---
title: Biomarkers
date: '2025-01-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39784260/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250109170938&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Our data suggest that plasma p-tau217 is a suitable screening
  method for clinical trials in CU populations given its logistic advantages. In scenarios
  where a more refined prediction of cognitive decline is mandated, Tau-PET (preferably
  in a combined algorithm with plasma p-tau217) would be the methodology of ...'
disable_comments: true
---
CONCLUSION: Our data suggest that plasma p-tau217 is a suitable screening method for clinical trials in CU populations given its logistic advantages. In scenarios where a more refined prediction of cognitive decline is mandated, Tau-PET (preferably in a combined algorithm with plasma p-tau217) would be the methodology of ...